通过Ck2控制和Src/Akt/Stat3减弱,Mcam可以稳定一种类似于光线原始的乳腺癌细胞状态
Ozlen Balcioglu1,2, Brooke L Gates1,2, David W Freeman1,2
1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
NPJ breast cancer
|September 14, 2024
概括
细胞表面的糖蛋白MCAM维持着原生细胞状态,驱动着基底类乳腺癌. 抑制MCAM,CK2或STAT3可能为内分泌抵抗性乳腺癌提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 分子医学是分子医学.
背景情况:
- 细胞状态的可塑性是组织发育和癌症进展的基础.
- 癌细胞经常模仿干细胞/祖细胞状态,导致瘤异质性和治疗耐药性.
研究的目的:
- 研究细胞表面糖蛋白MCAM在维持瘤性上皮细胞状态中的作用.
- 探索针对乳腺癌的MCAM,CK2和STAT3的治疗潜力.
主要方法:
- 使用Py230小鼠乳腺癌模型.
- 进行了MCAM敲击 (KD) 实验.
- 分析了 Ck2/Stat3 信号轴.
- 研究了瘤细胞状态和雌激素感应子群.
- 检查了人类瘤样本.
主要成果:
- MCAM KD破坏了光原体 (LP) 样细胞状态的稳定,导致切换到膜和基底状态.
- MCAM KD导致雌激素感应细胞的丧失和他莫西芬耐药性,这在CK2和STAT3抑制剂下是可逆的.
- 在体内,MCAM KD抑制了基底类瘤和特定原生细胞 (Sox10+Krt14+) 的产生.
- 在人类癌症中,MCAM损失与扩散的Luminal亚型相关,包括内分泌耐药的Luminal B癌症,并且不包括基本类亚型.
结论:
- MCAM对于维持致癌的LP样细胞状态至关重要,这种细胞状态驱动着基底样乳腺癌.
- 针对MCAM,CK2和STAT3为特定的乳腺癌亚型提供了一个有希望的治疗途径,特别是对内分泌系统有抵抗性的乳腺癌亚型.
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Positive Regulator Molecules
5.4K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.4K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K


